Post date September 19, 2023 Experience RayzeBio $358 million IPO The stock is listed on the Nasdaq Global Market
Post date August 15, 2023 Experience SSI Strategy acquisition of NDA Group We advised SSI Strategy on the acquisition
Post date July 28, 2023 Experience Immedica Pharma acquisition of pegzilarginase assets from Aeglea We advised Immedica on the transaction
Post date July 28, 2023 Experience BMS $35 million investment in Immatics We advised Immatics on the private placement of ordinary shares
Post date June 28, 2023 Experience Centogene strategic collaboration with Lifera We are advising Centogene on its joint venture with and convertible debt investment by Lifera
Post date June 27, 2023 Experience Noile-Immune Biotech ¥3.1 billion global IPO The shares are listed on the Tokyo Stock Exchange
Post date June 5, 2023 Experience Oculis Holding $40.25 million debut equity offering The shares are listed on the Nasdaq Global Market
Post date May 17, 2023 Experience Forbion European Acquisition combination with enGene We are advising Forbion European Acquisition on its de-SPAC transaction
Post date May 12, 2023 Experience GSK exclusive licensing agreement with Scynexis We advised GSK on the transaction
Post date May 9, 2023 Experience ACELYRIN $621 million IPO The stock is listed on the Nasdaq Global Select Market